Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer.

Gregory J Riely Egbert F Smit Myung-Ju Ahn Enriqueta Felip Font Suresh R Ramalingam Anne S Tsao Melissa Lynne Johnson Francesco GelsominoRaymond EsperErnest Nadal Michael D Offin Mariano Provencio PullaJeffrey ClarkeMaen HussainGregory A Otterson Ibiayi Dagogo-Jack Jonathan Wade Goldman Daniel MorgenszternAnn AlcasidTiziana UsariPaul S WisselKeith WilnerNuzhat PathanSvitlana TonkovydBruce E Johnson

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

-mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma.

Keyphrases

phase ii
open label
small cell lung cancer
clinical trial
wild type
squamous cell carcinoma
phase iii
phase ii study
advanced non small cell lung cancer
rectal cancer
drug administration